Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the hypoxanthine class of purine derivatives. Its molecular formula is C10H16N6O3 and it has a molecular weight of approximately 268.27 g/mol. The structure features a purinone core with an amino group at position 2 and a substituted ethylamino side chain at position 7 containing two hydroxy groups and one hydroxymethyl group. It is classified as experimental and does not have any approved medical indications or known clinical use as of now. The only identified biological target for this compound is purine nucleoside phosphorylase, suggesting potential activity in modulating purine metabolism[1][3]. No further pharmacological or clinical data are available.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-Amino-7-[2-(2-hydroxy-1-hydroxymethyl-ethylamino)-ethyl]-1,7-dihydro-purin-6-one.